Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon

NCT04547738 | Unknown

• 1 other identifier: HO2009/14-1
• Study Type: observational
• Target: 2,500
• Locations: 1 country
• Sites: 1

Brief Summary

Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections. Indeed, several studies showed that increased susceptibility and worsened disease course of HIV, tuberculosis (TB) and malaria in filarial endemic regions. Moreover, the investigators demonstrated that M. perstans infections polarize and suppress immune responses with likely consequences for concomitant infections and vaccine-induced protection. In addition, the investigators observed altered frequencies of natural killer and regulatory T and B cells in filarial and M. tuberculosis co-infected individuals and that M. perstans influences CD4+ T cell function and immune responses upon purified protein derivative antigen stimulation. Nevertheless, the consequences of manifestation of TB disease and influence on TB vaccination remains unknown. Thus, the trial aim to address two main questions with high clinical relevance: 1) Does filarial infection influence disease severity and recovery in tuberculosis patients? 2) Does filarial infection influence Bacille Calmette-Guérin (BCG)-induced protection against disease progression in vaccinated children?

Conditions

Tuberculosis

Keywords

filariae; tuberculosis; BCG vaccination

Outcome Measures

Primary Outcomes (1)

• Influence of filariae infection on TB disease outcome and BCG vaccination

  Does filarial infection influence tuberculosis disease severity and recovery under treatment and influence Bacille Calmette-Guérin (BCG)-induced protection against disease progression Parasitological diagnosis: * Blood smear for microfilaria detection using microscopy * DNA isolation from urine, blood and stool for helminth detection using LAMP and PCR technology * Helminth egg detection in urine and stool using Kato Katz technique * Skin snip for detection of Onchocerca volvulus infection TB diagnosis: * Chest radiography * Sputum smear and culture * GeneXpert * TST Test * Physical examination * Questionnaires to obtain medical, TB contact and treatment history

  3 years

Secondary Outcomes (1)

• Biomarkers for TB severity and BCG vaccination

  3 years

Study Arms (2)

Tuberculosis (TB) index patients

\- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment

Drug: TB treatment according to national guidelines

TB contacts

\- Children (5-17 years old), who had contact with TB index patients

Drug: TB treatment according to national guidelines

Interventions

TB treatment according to national guidelines DRUG

National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis

TB contacts; Tuberculosis (TB) index patients

Eligibility Criteria

• Age: 5 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

* TB positive individuals (older than 5 years) * TB contacts (children 5-17 years old)

You may qualify if:

• Patient is older than 5 years old
• Patient have BCG scare or get the BCG vaccination at birth
• Patient had no previous treatment of, tuberculosis or with at least one of the study drugs i.e. isoniazid,rifampicin, pyraziamide, ethambutol
• Patient have no history of hypersensitivity to rifampicin, or any of the above mentioned drugs
• Patient is not on any medication likely to interact with the study medication
• Patient have no history of or current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise (e.g., immunosuppressive drugs after organ transplant), or have no evidence of (previous) tuberculosis, Buruli ulcer or leprosy and no terminal illness (e.g., metastasized cancer)
• Patient have no mental condition
• Patient is able to take oral medication
• Patient have no mental condition including addiction with substance abuse e.g. alcohol
• Patient is willing to give informed pre-consent, and consent
• In case the patient is below 18, the parents or legal guardians were informed and provide consent

You may not qualify if:

• Patient is younger than 5 years old
• Patient have no BCG scare or miss the BCG vaccination at birth
• Patient had previous treatment of, tuberculosis or with at least one of the study drugs i.e. isoniazid,rifampicin, pyraziamide, ethambutol
• Patient have a history of hypersensitivity to rifampicin, or any of the above mentioned drugs
• Patient is on any medication likely to interact with the study medication
• Patient have a history of or current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise (e.g., immunosuppressive drugs after organ transplant), or evidence of (previous) tuberculosis, Buruli ulcer or leprosy; or terminal illness (e.g., metastasized cancer)
• Patient have a mental condition including addiction with substance abuse e.g. alcohol likely to interfere with possibility to comply with study protocol
• Patient is unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption
• Patient have a mental condition including addiction with substance abuse e.g. alcohol likely to interfere with possibility to comply with study protocol
• Patient is not willing to give informed pre-consent, and consent or withdrawal or consent
• In case the patient is below 18, were the parents or legal guardians were not informed and did not provide consent

Sponsors & Collaborators

• University Hospital, Bonn: lead

Study Sites (1)

University of Buea

Buea, Cameroon

RECRUITING

MeSH Terms

Conditions

Tuberculosis

Condition Hierarchy (Ancestors)

Mycobacterium Infections; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Officials

• Achim Hoerauf, Prof. Dr.

  UKB, IMMIP

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Samuel Wanji, Prof. Dr.

CONTACT

+237 77 72 43 84; swanji@yahoo.fr

Manuel Ritter, Dr.

CONTACT

+4928828711453; manuel.ritter@ukbonn.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prinicpal investigator

Study Record Dates

• First Submitted: September 4, 2020
• First Posted: September 14, 2020
• Study Start: December 1, 2020
• Primary Completion: October 1, 2023
• Study Completion: October 1, 2023
• Last Updated: November 23, 2021

Record last verified: 2021-11

Locations

CA (1)